SOTIO Completes Enrollment for Phase 3 Trial of DCVAC/PCa Immunotherapy
News
The Phase 3 trial evaluating the immunotherapy DCVAC/PCa in men with metastatic castration-resistant prostate cancer (mCRPC), has completed patient enrollment, according to trial sponsor, SOTIO. The treatment is being evaluated as ... Read more